pan> (the "U.S. Prospectus") is available on EDGAR at www.sec.gov
and a copy of the final prospectus supplement and accompanying base shelf prospectus relating to the Offering in Canada
(the "Canadian Prospectus") is available on SEDAR at www.sedar.com
. Alternatively, a copy of the U.S. Prospectus may be obtained from Goldman, Sachs & Co. at 200 West Street, New York, New York
10282, Attn: Prospectus Department, telephone: 866-471-2526, facsimile: 212-902-9316, email: email@example.com
and a copy of the Canadian Prospectus may be obtained from Goldman Sachs Canada Inc. at 77 King Street West, Suite 3400, Toronto, Ontario
M5K 1B7, Attn: Prospectus Department, telephone: 866-471-2526, facsimile: 212-902-9316, email: firstname.lastname@example.org
This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
Forward Looking Statements
This press release may contain forward-looking statements, including, but not limited to those related to the Company's intended use of proceeds from the
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Valeant Pharmaceuticals International, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical2
. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results3
. Valeant Pharmaceuticals To Host Investor Day4
. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 20125
. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash6
. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference7
. Valeant Pharmaceuticals Announces Management Change8
. Valeant Pharmaceuticals To Syndicate Incremental Loans9
. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors10
. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes11
. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes